PRESS RELEASE published on 08/17/2023 at 22:15, 2 years 3 months ago Moderna Clinical Trial Data Confirm Its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants
PRESS RELEASE published on 08/03/2023 at 12:30, 2 years 4 months ago Moderna Reports Second Quarter 2023 Financial Results and Provides Business Updates
PRESS RELEASE published on 07/13/2023 at 13:00, 2 years 4 months ago Moderna to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023
PRESS RELEASE published on 07/05/2023 at 13:00, 2 years 5 months ago Moderna Announces Global Regulatory Submissions For Its Respiratory Syncytial Virus (RSV) Vaccine, MRNA-1345
PRESS RELEASE published on 07/03/2023 at 07:00, 2 years 5 months ago Moderna Submits Regulatory Application to the European Medicines Agency for Its Updated COVID-19 Vaccine
PRESS RELEASE published on 06/22/2023 at 22:05, 2 years 5 months ago Moderna Files for FDA Authorization of Its Updated COVID-19 Vaccine
PRESS RELEASE published on 06/05/2023 at 14:00, 2 years 6 months ago Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma
PRESS RELEASE published on 06/01/2023 at 22:05, 2 years 6 months ago Moderna to Present at Upcoming Conferences in June 2023
PRESS RELEASE published on 05/30/2023 at 14:00, 2 years 6 months ago Moderna Announces Phase 2 Data on mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, to be Presented at the 2023 ASCO Annual Meeting
PRESS RELEASE published on 05/19/2023 at 13:00, 2 years 6 months ago Phase 1/2 Interim Data on Moderna's mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA), Presented at the 2023 ASGCT Annual Meeting
Published on 12/05/2025 at 14:00, 55 minutes ago Ocean Power Technologies Attending the 3rd Annual DealFlow Discovery Conference
Published on 12/05/2025 at 14:00, 55 minutes ago Bonk, Inc. Highlights Major Ecosystem Milestone: Launch of Regulated BONK ETP on SIX Swiss Exchange
Published on 12/05/2025 at 02:35, 12 hours 20 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 13 hours 55 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/05/2025 at 14:22, 33 minutes ago EQS-Adhoc: Jungheinrich AG: Jungheinrich expects to complete sale of its Russian subsidiary in 2026 and adjusts forecast for the 2025 financial year
Published on 12/05/2025 at 14:16, 38 minutes ago Advanced Blockchain AG: Successful Completion of Token Generation Event of Portfolio company Talisman
Published on 12/05/2025 at 14:10, 45 minutes ago The Kingdom of Saudi Arabia Launches a New Official Platform, "Saudi Properties", Ahead of the Non-Saudi Property Ownership Law
Published on 12/05/2025 at 13:45, 1 hour 10 minutes ago BingX Introduces Recurring Buy to Help Users Ride Out Crypto Market Swings
Published on 12/05/2025 at 13:00, 1 hour 55 minutes ago Zentra Group plc: Posting of Notice of Annual General Meeting
Published on 12/05/2025 at 13:58, 57 minutes ago RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE
Published on 12/05/2025 at 08:45, 6 hours 10 minutes ago Air Liquide va étendre et électrifier son unité de production d'oxygène à Shaanxi, soutenant ainsi l'engagement de la Chine à décarboner son industrie
Published on 12/05/2025 at 08:45, 6 hours 10 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/05/2025 at 08:42, 6 hours 13 minutes ago ENGIE - déclaration mensuelle du nombre total d'actions et de droits de vote composant le capital au 30 novembre 2025
Published on 12/04/2025 at 18:14, 20 hours 41 minutes ago Résiliation d'une convention conclue entre actionnaires
